1. Asensi M, Medina I, Ortega A, Carrertero J, Bano MC, Obrador E, Estrela JM (2002) Inhibition of cancer growth by resveratrol is related to its low bioavailability. Free Radical Biol Med 33: 387–398
2. Banerjee S, Bueso-Ramos C, Aggarwal BB (2002) Suppression of 7,12 dimethylbenz(a)anthracene-induced mammary carcinogenesis in rats by resveratrol: role of nuclear factor-kappa B, cyclooxygenase 2, and matrix metalloprotease 9. Cancer Res 62: 4945–4954
3. Bertelli AAE, Giovannini R, Stradi R, Urien S, Tillement JP, Bertelli A (1996) Kinetics of trans- and cis-resveratrol (3,4′,5-trihydroxystilbene) after red wine oral administration in rats. Int J Clin Pharm Res 16: 77–81
4. Bhat KPL, Lantvit D, Christov K, Mehta RG, Moon RC, Pezzuto JM (2001) Estrogenic and antiestrogenic properties of resveratrol in mammary tumor models. Cancer Res 61: 7456–7463
5. Chun YJ, Kim MY, Guengerich FP (1999) Resveratrol is a selective human cytochrome P450 1A1 inhibitor. Biochem Biophys Res Commun 262: 20–24